Metcela Inc. Completes the Series C Financing of Total $14 Million | Metcela Inc.
Summary
Metcelas strong belief in minimally invasive and autologous treatment, not requiring immunosuppressive agents and prolonged hospitalization, is attracting more attention during global pandemic that the world have faced for the past 2 years. In light of these circumstances, Metcela has conducted this fundraising in order to advance the establishment of a commercial manufacturing infrastructure for autologous products, and to further accelerate the research and development of other pipelines. Metcela will also continue to strengthen its relationship with academic partners and medical community in the areas of basic research to have better understanding of and explore new applicable indications for its fibroblast-based technologies as well as newly added cardiac stem cell pipeline.Metcela plans to establish a new R&D base in Cyberdynes Cybernics A Building, currently under construction in KING SKYFRONT in Tonomachi, Kawasaki. Websitehttps://www.japanlifeline.com/Sony Ventures Corporation manages Sony Innovation Fund (SIF), which invests in all stages of emerging technology companies as well as in startups solving global environmental challenges. Websitehttps://reazon.jp/Metcela Inc., established in 2016, is a clinical-stage biotechnology startup pioneering the research and development of fibroblast and stem cell-based therapy for chronic diseases that currently have limited therapeutic options.